Evidence map›Paper›PMID 34283288›Full record

ArticleJournal of cancer research and clinical oncology2022

Colonization with multidrug-resistant organisms impairs survival in patients with hepatocellular carcinoma.

Vera Himmelsbach, Mate Knabe, Phillip G Ferstl, Kai-Henrik Peiffer, Jan A Stratmann, Thomas A Wichelhaus, Michael Hogardt, Volkhard A J Kempf, Stefan Zeuzem, Oliver Waidmann and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of cancer research and clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. [Therapy-relevant antibiotic resistances in a One Health context].Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz · 2023
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Vera HimmelsbachDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Mate KnabeDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Phillip G FerstlDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Kai-Henrik PeifferDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Jan A StratmannUniversity Cancer Center, Goethe University Hospital, Frankfurt/Main, Germany.
Thomas A WichelhausInstitute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
Michael HogardtInstitute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
Volkhard A J KempfInstitute of Medical Microbiology and Infection Control, Goethe University Hospital, Frankfurt/Main, Germany.
Stefan ZeuzemDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Oliver WaidmannDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Fabian FinkelmeierDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany.
Olivier BalloDepartment of Medicine, Gastroenterology, Hepatology and Endocrinology, Goethe University Frankfurt, Frankfurt/Main, Germany. olivier.ballo@kgu.de.ORCID http://orcid.org/0000-0003-1634-1988
Goethe University Frankfurt · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionMDRO-colonization has been shown to impair survival in patients with hematological malignancies and solid tumors as well as in patients with liver disease. Despite the increasing spread of multidrug-resistant organisms (MDRO), its impact on patients with hepatocellular carcinoma (HCC) has not been studied. We conducted this retrospective study to analyze the impact of MDRO-colonization on overall prognosis in HCC patients. MATERIALS AND

methodsAll patients with confirmed HCC diagnosed between January 2008 and December 2017 at the University Hospital Frankfurt were included in this study. HCC patients with a positive MDRO screening before or within the first 90 days after diagnosis of HCC were defined as colonized HCC patients, HCC patients with a negative MDRO screening were defined as noncolonized HCC patients.

results59 (6%) colonized and 895 (94%) noncolonized HCC patients were included. Enterobacterales with extended-spectrum β-lactamase-like phenotype with or without resistance to fluoroquinolones (ESBL/ ± FQ) were the most frequently found MDRO with 59%, followed by vancomycin-resistant Enterococcus faecium with 37%. Colonized HCC patients had more severe cirrhosis and more advanced HCC stage compared to noncolonized HCC patients. Colonized HCC patients showed an impaired survival with a median OS of 189 days (6.3 months) compared to a median OS of 1001 days (33.4 months) in noncolonized HCC patients. MDRO-colonization was identified as an independent risk factor associated with survival in multivariate analysis.

conclusionMDRO-colonization is an independent risk factor for survival in patients with HCC highlighting the importance of regular MDRO screening, isolation measures as well as interdisciplinary antibiotic steward-ship programs to guide responsible use of antibiotic agents.

Indexed as

Carcinoma, HepatocellularLiver NeoplasmsAnti-Bacterial AgentsDrug Resistance, Multiple, BacterialHumansRetrospective StudiesRisk FactorsAnti-Bacterial AgentsAntibioticsAntibiotic steward-shipESBLHepatocellular carcinomaInfectionLiver cancerMultidrug-resistant organismsSurvivalVRE

Identifiers

PMID34283288
PMCPMC9114096
OpenAlexW3186203154

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.